Karen Vanhoorelbeke Selected Research

von Willebrand Factor

1/2022	Deletion of platelet CLEC-2 decreases GPIbα-mediated integrin αIIbβ3 activation and decreases thrombosis in TTP.
1/2022	Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis.
10/2021	Conformational plasticity of ADAMTS13 in hemostasis and autoimmunity.
2/2021	Detailed histological analysis of a thrombectomy-resistant ischemic stroke thrombus: a case report.
1/2021	The von Willebrand Factor A1 domain mediates thromboinflammation, aggravating ischemic stroke outcome in mice.
1/2021	Plasma and rhADAMTS13 reduce trauma-induced organ failure by restoring the ADAMTS13-VWF axis.
1/2021	Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients.
1/2020	Von Willebrand factor and ADAMTS13 impact on the outcome of Staphylococcus aureus sepsis.
1/2020	von Willebrand factor increases in experimental cerebral malaria but is not essential for late-stage pathogenesis in mice.
1/2020	Structural analysis of ischemic stroke thrombi: histological indications for therapy resistance.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karen Vanhoorelbeke Research Topics

Disease

48	Thrombotic Thrombocytopenic Purpura 10/2022 - 03/2006
33	Thrombosis (Thrombus) 02/2022 - 05/2002
9	Thrombocytopenia (Thrombopenia) 01/2022 - 11/2009
8	Hemorrhage 01/2022 - 04/2002
8	Ischemic Stroke 02/2021 - 04/2009
7	Thrombotic Microangiopathies 01/2021 - 03/2014
6	acquired Thrombotic thrombocytopenic purpura 11/2020 - 02/2008
5	Vascular System Injuries 10/2021 - 01/2007
5	Stroke (Strokes) 02/2021 - 04/2009
5	Hemolytic Anemia 04/2017 - 09/2010
4	Inflammation (Inflammations) 01/2022 - 01/2017
4	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 01/2017
4	von Willebrand Diseases (von Willebrand's Disease) 10/2018 - 04/2002
3	COVID-19 08/2022 - 01/2021
3	Sepsis (Septicemia) 01/2022 - 10/2007
3	Type 2 von Willebrand Disease 10/2018 - 04/2002
3	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2016 - 10/2010
2	Infections 08/2022 - 01/2020
2	Critical Illness (Critically Ill) 01/2022 - 01/2021
2	Purpura 01/2021 - 11/2018
2	Brain Ischemia (Cerebral Ischemia) 01/2021 - 01/2016
2	Malaria 01/2020 - 01/2019
2	Fibrosis (Cirrhosis) 08/2018 - 08/2017
2	Obesity 01/2018 - 07/2015
2	Cerebral Infarction 01/2016 - 10/2015
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2009 - 08/2007
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2009 - 08/2007
1	Hepatitis D 08/2022
1	Breakthrough Infections 01/2022
1	Endocarditis 11/2021
1	Calcinosis 02/2021
1	Venous Thromboembolism 02/2021
1	Wounds and Injuries (Trauma) 01/2021
1	Reperfusion Injury 01/2021
1	Thromboinflammation 01/2021
1	Cerebral Malaria 01/2020
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2019
1	Edema (Dropsy) 01/2019
1	deficiency Von willebrand factor 11/2018
1	Abdominal Aortic Aneurysm 11/2018
1	Rare Diseases (Rare Disease) 11/2018

Drug/Important Bio-Agent (IBA)

35	von Willebrand FactorIBA 01/2022 - 04/2002
26	thiamine triphosphorate (TTP)IBA 10/2022 - 03/2006
17	AutoantibodiesIBA 11/2021 - 12/2014
16	Metalloproteases (Metalloproteinases)IBA 11/2021 - 10/2007
13	ThrombospondinsIBA 01/2021 - 10/2007
12	DisintegrinsIBA 01/2021 - 10/2007
11	AntibodiesIBA 08/2022 - 09/2004
10	CollagenIBA 02/2022 - 05/2002
9	AntigensIBA 01/2021 - 03/2006
9	Glycoproteins (Glycoprotein)IBA 01/2019 - 09/2004
8	Monoclonal AntibodiesIBA 08/2022 - 05/2002
7	EpitopesIBA 08/2022 - 09/2004
7	EnzymesIBA 01/2021 - 04/2002
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2008
5	FibrinIBA 01/2022 - 10/2015
4	DNA (Deoxyribonucleic Acid)IBA 08/2022 - 08/2017
4	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2022 - 03/2006
4	IntegrinsIBA 01/2022 - 09/2004
3	Proteins (Proteins, Gene)FDA Link 10/2022 - 11/2018
3	Hemostatics (Antihemorrhagics)IBA 01/2021 - 07/2011
3	ImmunosorbentsIBA 10/2020 - 04/2002
3	ADAMTS13 ProteinIBA 01/2017 - 03/2006
3	Fibrinolysin FDA Link 01/2017 - 03/2014
3	Platelet Glycoprotein GPIb-IX Complex (Glycoprotein Ib)IBA 06/2006 - 05/2002
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022 - 12/2007
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 09/2010
2	Platelet Membrane GlycoproteinsIBA 01/2019 - 10/2012
2	estropipate (Ogen)FDA LinkGeneric 01/2016 - 10/2015
2	Collagen ReceptorsIBA 01/2012 - 01/2007
2	adhesion receptorIBA 04/2009 - 09/2005
1	caplacizumabIBA 01/2022
1	Eptifibatide (Integrilin)FDA Link 01/2022
1	Fibrinogen (Factor I)FDA Link 01/2022
1	BNT162 VaccineIBA 01/2022
1	Immunoglobulin G (IgG)IBA 11/2021
1	PolymersIBA 10/2021
1	Eosine Yellowish-(YS) (Eosin)IBA 02/2021
1	Feulgen stainIBA 02/2021
1	Hematoxylin (Haematoxylon)IBA 02/2021
1	Coloring Agents (Dyes)IBA 02/2021
1	AntithrombinsIBA 02/2021
1	VaccinesIBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	SuspensionsIBA 01/2021
1	Biological ProductsIBA 01/2020
1	CytokinesIBA 01/2020
1	Anti-Idiotypic AntibodiesIBA 01/2019
1	Rituximab (Mabthera)FDA Link 11/2018
1	Angiotensin IIIBA 11/2018

Therapy/Procedure

3	Therapeutics 01/2020 - 11/2015
2	Thrombectomy 02/2021 - 01/2020
2	Transplantation 10/2015 - 12/2009
1	Surgical Instruments (Clip) 01/2022
1	Erythrocyte Transfusion 01/2022
1	Extracorporeal Membrane Oxygenation 01/2022
1	Oxygenators 01/2022
1	Oral Administration 01/2022
1	Resuscitation 01/2021
1	Kidney Transplantation 01/2019